Brought to you by 
Berna Biotech buys Rhein Biotech in $257mm cash/stock deal
02 Jul 2002
Executive Summary
Switzerland-based Berna Biotech (serums/vaccines for treating infectious diseases) is acquiring 4.05mm shares of Dutch vaccine developer Rhein Biotech for about $257mm (Euro277mm) in cash and stock--or over three times Rhein's 2001 sales revenue of $76.3mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Berna Biotech buys Rhein Biotech in $257mm cash/stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice